Evaluation of the hepatitis B antenatal screening and neonatal immunization program in Amsterdam, 1993-1998.
In the enhanced antenatal hepatitis B screening and neonatal immunization program in Amsterdam, 691 hepatitis B surface antigen (HBsAg) positive expectant mothers were reported in the period 1993-1998. The coverage of the screening was calculated at 97%. HBsAg-prevalence was high in women from Ghana and South-East Asia, and lowest in Dutch women. Hepatitis B immune globulin (HBIg) was administered within 24h to 95.9% of the neonates; 99.7% completed the vaccination series. About 6 weeks after the third vaccination the titer antiHBs was > or =100 IU/l in 85% of children; in 12% the titers were 10-100 IU/l; 3% had titers <10 IU/l, of whom 3/521 initially had HBsAg. Low birth weight (OR 3.77), being a boy (OR 1.64) and country of origin were predictors of low postvaccination titers. Coordinated by 0.5 full time equivalent (fte) additional staff, the program was relatively cheap and successful.
van Steenbergen
J E
JE
Cluster Infectious Diseases, Municipal Health Service Amsterdam, GG & GD, P.O. Box 2220, 1000 CE, Amsterdam, The Netherlands.
Leentvaar-Kuijpers
A
A
Baayen
D
D
Dukers
H T
HT
van Doornum
G J
GJ
van den Hoek
J A
JA
Coutinho
R A
RA
D000328:Adult; D005006:Ethnicity; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage*; D006801:Humans; D007112:Immunity, Maternally-Acquired; D017589:Immunization Programs; D007115:Immunization Schedule; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D008297:Male; D008403:Mass Screening; D008427:Maternal Health Services / Q000458:organization & administration / Q000706:statistics & numerical data; D009426:Netherlands / Q000453:epidemiology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000453:epidemiology*; D011295:Prenatal Care; D015995:Prevalence; D015397:Program Evaluation
D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines